



2014 ONCOLOGY DRUG REPORT

World's Largest Active Resource for Decision Making

Oncology
COMPANIES

Cancer
MOLECULES

Cancer
INDICATIONS

Clinical
COMPANIES

Preclinical
COMPANIES

Discovery
COMPANIES

Content:

<i>Foreword</i>	4
<i>List of Figures</i>	13
<i>List of Tables</i>	17
<i>List of Boxes</i>	21
<i>List of Clinical Companies</i>	22
<i>List of Pre-clinical Companies</i>	27
<i>List of Discovery Companies</i>	28
<i>Executive Summary</i>	31

Section A : Oncology Companies with Active Drug Development Pipeline - Infographics

- ***Worldwide Distribution of Companies with Active Cancer Drug Pipeline*** **34**
 - Quantitative Estimation of Cancer Drug Developers present in U.S.A vs. Europe vs. Asia vs. Canada vs. Australia vs. Rest of the World (931 Companies)
 - Quantitative Estimation of Clinical, Preclinical & Discovery stage companies present in U.S.A (468 companies)
 - Quantitative Estimation of Clinical, Preclinical & Discovery stage companies present in Europe (270 companies)
 - Quantitative Estimation of Clinical, Preclinical & Discovery stage companies present in Asia (132 companies)
- ***Country-wise Distribution of Companies (Clinical, Preclinical & Discovery) having Active Cancer Drug Development Pipeline in Europe and Asia Region.*** **35**
 - To identify best and emerging countries, for promoting cancer drug development in the region.
- ***State-wise Distribution of Companies (Clinical, Preclinical & Discovery) having Active Cancer Drug Development Pipeline in U.S.A.*** **36**
 - To explore the Top cancer innovation supporting States in United States.
- ***Distribution of 931 companies, on the basis of year of Establishment*** **37**
 - To explore the emergence of Cancer Drug Discovery And Development.
- ***Quantitative Estimation of Oncology Drug Developers on the basis of Human Resource Employed.*** **38**
 - Top 10 cancer drug development companies (in terms of employee numbers), with their total employees vs. total number of R&D staff for past three consecutive years.

Section B : Active Oncology Drugs and Targets in Development - Key Intelligence	39
<ul style="list-style-type: none"> <i>Distribution of Oncology Molecules in Clinical Development</i> (2237 molecules) <ul style="list-style-type: none"> Total number of Small, Biologics and Non Biological complex molecules in clinical development. Total number of cancer molecules in development in USA, Europe, Asia and Rest of the World. Molecule development strategies - Top 10 companies vs. remaining 921 companies. 	40
<ul style="list-style-type: none"> <i>Top 20 Oncology Drug Development Companies</i> (In terms of molecules in Clinical Development) <ul style="list-style-type: none"> Top 20 Cancer clinical development companies, their molecule types (small, biologics & NBCM), clinical phases and total Indications of development. 	42
<ul style="list-style-type: none"> <i>Monoclonal Antibodies in Clinical Development</i> (173 molecules) <ul style="list-style-type: none"> Monoclonal antibodies in clinical development with developer and partner name, antibody target, isotype and drug development indications. 	44
<ul style="list-style-type: none"> <i>Monoclonal Antibodies in Pre-Clinical Development</i> (193 molecules) <ul style="list-style-type: none"> Monoclonal antibodies in preclinical & discovery development with developer name, antibody target and drug development indications. 	49
<ul style="list-style-type: none"> <i>Cancer Vaccines in Clinical Development</i> (134 molecules) <ul style="list-style-type: none"> Cancer Vaccines in clinical development with short description, developer and partner name, drug target and development Indications. 	52
<ul style="list-style-type: none"> <i>Cancer Vaccines in Pre-Clinical Development</i> (50 molecules) <ul style="list-style-type: none"> Cancer Vaccines in Pre-clinical & Discovery development with developer name, drug target and development Indications. 	58
<ul style="list-style-type: none"> <i>Cancer Targeting Antibodies Drug Conjugates in Clinical Development</i> (42 molecules) <ul style="list-style-type: none"> ADCs in clinical development, with short description of antibody and toxin attached; developer and partner name; its target and development Indications. 	59
<ul style="list-style-type: none"> <i>Cancer Targeting Radio-Immuno Conjugates in Clinical Development</i> (10 molecules) <ul style="list-style-type: none"> Radio-Immuno Conjugates in clinical development, with short description of antibody and radio isotope attached; developer and partner name; its target and development Indications. 	61
<ul style="list-style-type: none"> <i>Cancer Targeting Recombinant/Fusion Protein Therapies in Development</i> (49 molecules) <ul style="list-style-type: none"> Recombinant/Fusion Protein in clinical development with short description, developer and partner name, their targets and development Indications. 	62
<ul style="list-style-type: none"> <i>Cancer Targeting Synthetic Peptides in Clinical Development</i> (19 molecules) <ul style="list-style-type: none"> Synthetic peptides/proteins in clinical development with short description, developer and partner name, their targets and development Indications. 	64
<ul style="list-style-type: none"> <i>Oncolytic Virus Based/Gene Therapies in Clinical Development</i> (33 molecules) <ul style="list-style-type: none"> Oncolytic virus based Therapies in clinical development with short description, its developer and partner name; drug target and development Indications. 	65
<ul style="list-style-type: none"> <i>Cell Based Therapies for cancer treatment in Clinical Development</i> (19 molecules) <ul style="list-style-type: none"> T-Cell, Stem Cell and Other Cell based therapies in clinical development with short description, its developer and partner name; drug target and development Indications. 	67
<ul style="list-style-type: none"> <i>Other Biological Therapies in Clinical Development</i> (23 molecules) <ul style="list-style-type: none"> Remaining biological therapies in clinical development for cancer treatment, with short description, their developer and partner name; drug target and development Indications. 	68

□ <i>Protein Kinases – An Emerging Class of Cancer Drug Targets</i>	69
<p>Protein kinases vs other cancer drug targets in clinical development; Comparative developmental profile of protein kinases, with their molecules and indications numbers. Top four kinases classes targeting cancer with their molecule numbers; Cancer targeting kinases development strategies - Top 10 companies vs. Remaining 921 companies. Established kinases in cancer drug discovery, their FDA approval years; Annual sales and indications. Anticipated protein kinases launch In 2014-15, with cancer indications.</p>	
□ <i>Complete List of Emerging Cancer Drug Targets (228 Targets)</i>	
<p>Protein Kinases as Cancer Drug Targets -Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target. <i>(55 Major Protein Target Classes)</i></p>	72
<p>Tumor Necrosis Factors as Cancer Drug Targets -Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target. <i>(11 Major Protein Targets)</i></p>	80
<p>G-coupled Receptors as Cancer Drug Targets -Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target. <i>(9 Major Protein Targets)</i></p>	82
<p>Tumor Surface Antigens as Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target. <i>(22 Major Protein Targets)</i></p>	83
<p>Transcription Factors as Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target. <i>(14 Major Protein Targets)</i></p>	85
<p>Targeting Cellular Metabolites as Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development for the target. <i>(14 Major Protein Targets)</i></p>	87
<p>Growth Factor as Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development. <i>(8 Major Protein Targets)</i></p>	89
<p>Miscellaneous Other Cancer Drug Targets –Target Name, Gene, Protein Family, Cellular Location & Functions, Short Description with drugs in clinical development. <i>(95 Targets)</i></p>	90

Section C : Oncology Indications in various Developmental Stages- *Intelligence* **103**

□ <i>Distribution of Oncology Indications in Clinical Development (4264 indications)</i>	104
<p>Division of 4264 indications for 2237 Molecules, in drugs types – Small, Biologic and NBCM. Geographic distribution of Clinical Indications and its correlation with number of molecules from similar region in development; Phase-Wise Breakup of total Indications; Cancer Clinical Indications strategies - Top 10 companies vs. remaining 513 companies; Comparative analysis on the preference of Top 10 companies for Small Molecule Vs. Biologics, in compare to remaining 513 companies.</p>	
□ <i>Drug Development Strategies- Top 10 Companies vs. Remaining 921 Companies</i>	105
<p>A competitive intelligence de-marking the preference of Large Pharma Majors to Small Innovators - their choice of targets; cancer indications and types of molecules development.</p>	

- ***Drug Development Profile & Pipeline Analysis - Lung Cancer*** **106**
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:- NSCLC
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
 Monoclonal Antibodies, Vaccines and other Biologics in development.
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
 Strong Pipeline Companies with highest number of molecules against NSCLC;
 Top 10 companies *vs.* others strategies in Lung Cancer Drug Development.
- Pipeline Analysis:-*** SCLC **114**
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Drug Development Profile & Pipeline Analysis - Breast Cancer*** **115**
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:-
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
 Monoclonal Antibodies, Vaccines and other Biologics in development.
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
 Strong Pipeline Companies with highest number of molecules against Breast cancer;
 Top 10 companies *vs.* others strategies in Breast Cancer Drug Development.
- ***Drug Development Profile & Pipeline Analysis - Colorectal Cancer*** **123**
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:-
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
 Monoclonal Antibodies, Vaccines and other Biologics in development.
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
 Strong Pipeline Companies with highest number of molecules against Colorectal cancer;
 Top 10 companies *vs.* others strategies in Colorectal Cancer Drug Development.
- ***Drug Development Profile & Pipeline Analysis - Melanoma Cancer*** **129**
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:-
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
 Monoclonal Antibodies, Vaccines and other Biologics in development.
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
 Strong Pipeline Companies with highest number of molecules against Melanoma cancer;
 Top 10 companies *vs.* others strategies in Melanoma Cancer Drug Development.
- Drug Development Pipeline:-*** Other Skin Cancers including Non-Melanoma Cancers.
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Drug Development Profile & Pipeline Analysis - Prostate Cancer*** **136**
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:-
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Monoclonal Antibodies, Vaccines and other Biologics in development.

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Strong Pipeline Companies with highest number of molecules against Prostate cancer;

Top 10 companies *vs.* others strategies in Prostate Cancer Drug Development.

□ **Drug Development Profile & Pipeline Analysis - Ovarian Cancer** **143**

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Pipeline Analysis:-

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Monoclonal Antibodies, Vaccines and other Biologics in development.

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Strong Pipeline Companies with highest number of molecules against Ovarian cancer;

Top 10 companies *vs.* others strategies in Ovarian Cancer Drug Development.

Drug Development Pipeline:- Gynaecologic Malignancies.

Cervical Cancer - Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners and targets).

Fallopian Tube Cancer -Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).

Peritoneal Cancer - Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners and targets).

Endometrial Cancer - Detailed Ph III, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

□ **Drug Development Profile & Pipeline Analysis - Pancreatic Cancer** **151**

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Pipeline Analysis:-

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Monoclonal Antibodies, Vaccines and other Biologics in development.

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Strong Pipeline Companies with highest number of molecules against Pancreatic cancer;

Top 10 companies *vs.* others strategies in Pancreatic Cancer Drug Development.

Drug Development Pipeline:- Gastrointestinal Tract Cancers.

Oesophageal Cancer- Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners & targets).

Biliary Tract Cancer -Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).

Gallbladder Cancer - Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).

Cholangiocarcinoma -Detailed Ph III, Ph II, Ph I & preclinical Pipeline (including developers, partners & targets).

Anal Cancer - Detailed Ph III, Ph II, Ph I Pipeline (including developers, partners and targets).

Gastrointestinal Stromal Tumor- Detailed Ph III, Ph II, Ph I & Preclinical Pipeline (including developers, partners and targets).

□ **Drug Development Profile & Pipeline Analysis - Hepatocellular Carcinoma** **158**

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Pipeline Analysis:-

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

□ **Drug Development Profile & Pipeline Analysis - Gastric Cancer** **161**

An Overview to Disease, Epidemiology ; Current Market Size & Forecast;

Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;

Pipeline Analysis:-

Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

- ***Drug Development Profile & Pipeline Analysis - Multiple Myeloma*** **163**
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:-
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Drug Development Profile & Pipeline Analysis - Leukemia*** **165**
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
Pipeline Analysis:- Leukemia
 Acute Myeloid Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
 Acute Myelogenous Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
 Acute Lymphoid Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
 Acute Lymphocytic Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
 Chronic Myeloid Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
 Chronic Myelogenous Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
 Chronic Myelomonocytic Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
 Chronic Lymphoid Leukemia - Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline.
- ***Drug Development Profile & Pipeline Analysis - Non-Hodgkin Lymphoma*** **171**
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
 Top Selling Chemotherapies & Targeted Drugs -their Annual Sales & Forecast;
Pipeline Analysis:-
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
Pipeline Analysis:- Waldenstrom's Macroglobulinemia
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Drug Development Profile & Pipeline Analysis - Hodgkin Lymphoma*** **175**
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
 Top Selling targeted therapies -their Annual Sales & Forecast;
Pipeline Analysis:-
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Drug Development Profile & Pipeline Analysis- Brain Cancer (including Glioblastoma)*** **176**
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
 Top Selling targeted therapies -their Annual Sales & Forecast;
Pipeline Analysis:- Glioblastoma
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
Neuroblastoma - Detailed PhIII, Ph II, Ph I & Preclinical Pipeline (including developers, partners & targets).
Medulloblastoma - Detailed PhIII, Ph II, Ph I, Preclinical Pipeline (including developers, partners & targets).
Anaplastic Astrocytoma- Detailed PhIII, Ph II, Ph I Pipeline (including developers, partners & targets).
- ***Drug Development Profile & Pipeline Analysis- Head & Neck Cancer*** **179**
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
 Top Selling targeted therapies -their Annual Sales & Forecast;
Pipeline Analysis:- Glioblastoma
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;

Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).

Nasopharynx Cancer- Detailed PhIII, Ph II, Ph I Pipeline (including developers, partners & targets).

Oral Cancer- Detailed PhIII, Ph II, Ph I, Preclinical Pipeline (including developers, partners & targets).

- ***Drug Development Profile & Pipeline Analysis - Renal Cell Carcinoma*** **182**
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
 Top Selling targeted therapies -their Annual Sales & Forecast;
Pipeline Analysis:-
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
Wilm's Tumor - Detailed PhIII, Ph II, Ph I & Preclinical Pipeline (including developers, partners & targets).
- ***Drug Development Profile & Pipeline Analysis - Bladder Cancer*** **185**
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
 Top Selling targeted therapies -their Annual Sales & Forecast;
Pipeline Analysis:-
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Drug Development Profile & Pipeline Analysis - Thyroid Cancer*** **187**
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
 Top Selling targeted therapies -their Annual Sales & Forecast;
Pipeline Analysis:-
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Drug Development Profile & Pipeline Analysis - Sarcoma*** **189**
 An Overview to Disease, Epidemiology ; Current Market Size & Forecast;
 Top Selling targeted therapies -their Annual Sales & Forecast;
Pipeline Analysis:-
 Active Ph III Molecules -Key Partners, targets, PhIII clinical trial design & Expected Launch;
 Detailed PhIII, Ph II, Ph I, Preclinical & Discovery Pipeline (including developers, partners and targets).
- ***Other Rare Cancer Indications - Developmental Pipeline*** Detailed PhIII, Ph II, Ph I, Pre clinical & Discovery Pipeline (including developers, partners, targets and indications). **191**
- ***Orphan Drug Status drugs in development for Cancer Treatment*** **192**
Name of Drug and Developer, its Orphan drug Indications and Orphan status providing agencies - US FDA and EMEA.
- ***US FDA New Oncology Drug Approvals - 2013*** **195**
 Developer, Approval month, Partner, Drug's Proprietary Name, Approved Indication.
- ***Oncology Clinical Pipeline - Major Phase III Failures - 2013*** **196**
 Ph III Molecules-Key Partners & expected Launch ; Ph II & Ph I Clinical Pipeline (including partners).

Section D : Individual Oncology Company Profile (with Active Clinical Pipeline) **197**

□ *A to Z Alphabetical Profiles of Cancer Clinical Drug Developer Companies (523 Companies)*

Individual company Pages includes: **Company Profile** - Key technology platform, Oncology centred deals, collaborations and business insights, key investors and key partners.

Clinical Pipeline Profile– Drug name, its target description, various development indications for cancer cure with current clinical trials and trials status (Active, Recruiting, Completed etc), FDA/EMEA Orphan drug status, Special Protocol Assessment , fast track approvals etc; company's pre-clinical & discovery pipeline.

Management Profile –Address, Contact phone number, e-mail, employees number range, Key Decision Maker (CXOs) names, designation with e-mail & LinkedIn IDs,, ownership and valuation status, Listed Stock Exchange and its ticker code, market capitalization (as on 17th April 2014).

Section E : Individual Oncology Company Profile (with Active PreClinical Pipeline) **796**

□ *A to Z Alphabetical Profiles of Cancer Preclinical Drug Developer Companies (360 Companies)*

Individual company Pages includes: **Company Profile** - Key technology platform, Oncology centred deals, collaborations and business insights, key investors and key partners.

Pre-Clinical Pipeline Profile – Drugs name, its targets, with details of its development for various indications for cancer cure, FDA/EMEA Orphan drug status, company's pre-clinical pipeline.

Management Profile –Address, Contact phone number, e-mail, employees number range, key management people (CXOs) name and designation, ownership and valuation status, Listed Stock Exchange and its ticker code, market capitalization (as on 17th April 2014).

Section F : Individual Oncology Company Profile (with Active Discovery Pipeline) **1011**

□ *A to Z Alphabetical Profiles of Cancer Discovery stage Companies (48 Companies)*

Individual company Pages includes: **Company Profile** - Key technology platform, Oncology centred deals, collaborations and business insights, key investors and key partners.

Discovery Pipeline Profile – Drug name, its targets, with details, of its development for various indications for cancer cure.

Management Profile –Address, Contact phone number, e-mail, employees number range, key management people (CXOs) name and designation, ownership and valuation status, Listed Stock Exchange and its ticker code, market capitalization (as on 17th April 2014).

Appendix A: Country Wise List of 931 Companies..... 1038

Appendix B: Complete 2237 Molecules List, along with their Developer's Name..... 1041

List of Figures:

Section A : Oncology Companies with Active Drug Development Pipeline- *Infographics* 33

Figure A.1	Qualitative Estimation of Oncology Drug Developers present in U.S.A vs. Europe vs. Asia vs. Australia vs. Canada vs. Rest of the World (931 Active Companies).	34
Figure A.2	Quantitative Estimation of clinical, preclinical & discovery companies present in U.S.A (468 companies)	34
Figure A.3	Quantitative Estimation of clinical, preclinical & discovery companies present in Europe (270 companies)	34
Figure A.4	Quantitative Estimation of clinical, preclinical & discovery companies present in Asia (132 companies)	34
Figure A.5	Showing all individual 19 Countries in Europe and 8 Countries in Asia , along with the individual oncology focused companies present in these countries.	35
Figure A.6	Bar Graph for Country-wise distribution of Companies (Clinical, Preclinical & Discovery) having Active Oncology drug development Pipeline in Europe Region.	35
Figure A.7	Bar Graph for Country-wise distribution of Companies (Clinical, Preclinical & Discovery) having Active Oncology drug development Pipeline in Asia Region.	35
Figure A.8	Showing all individual 28 States in U.S.A , along with the individual number of oncology focused companies present in these States.	36
Figure A.9	Bar Graph for State-wise distribution of Companies (Clinical, Preclinical & Discovery) having Active Oncology drug development Pipeline in U.S.A	36
Figure A.10	Distribution of Active Cancer Drug Developers on the basis of year of Formation/Incorporation.	37
Figure A.11	Bar Graph showing incorporation pattern of cancer drug developers form 1991 onwards.	37
Figure A.12	Division of 931 cancer drug development companies on the basis of Human Resource employed.	38

Section B : Active Oncology Drugs & Targets in Development - *Intelligence* 39

Figure B.1	Distribution of Active Cancer Molecules in various Developmental Stages among Small, Biologics & others (2237 Molecules).	40
Figure B.2	Division of total cancer molecules in development among U.S.A, Europe, Asia & Rest of the World.	40
Figure B.3	Molecule Development Strategies:- A. Total molecules in development – Top 10 companies vs. remaining 921 companies. B. Top 10 companies - Small Molecules vs. Biologics. C. Remaining 921 companies - Small Molecules vs. Biologics.	40
Figure B.4	Clinical phase-wise (Ph I/PhII/PhIII), Preclinical & Discovery stage distribution of 2237 molecules.	41
Figure B.5	Phase-wise distribution of Small Molecules in various developmental stages for cancer treatment.	41
Figure B.6	Phase-wise distribution of Biologics in various developmental stages for cancer treatment.	41
Figure B.7	Clinical phase-wise division of cancer molecules in development in U.S.A, Europe, Asia & RoW.	41
Figure B.8	Protein Kinase in cancer drug development A. Total number of Targets in Development – Protein Kinases vs. others. B. Total number of Molecules – Protein Kinases vs. others. C. Clinical phase-wise distribution of Protein Kinases in cancer drug development.	69
Figure B.9	Distribution of total Kinases in cancer clinical development in U.S.A, Europe, Asia & RoW.	69
Figure B.10	Top four Protein Kinases (Targets) in cancer clinical drug development (w.r.t molecules in development).	69
Figure B.11	Top three cancer Indications with highest numbers of Protein Kinases in clinical development.	69
Figure B.12	Protein Kinases Molecules development Strategies:- A. Total Kinases in development – Top 10 companies vs remaining 921 companies. B. Top 10 companies – clinical phase-wise distribution of Protein Kinases. C. Remaining 921 companies - clinical phase wise distribution of Protein Kinases.	69

Section C: Oncology Indications in various Development Stages - Intelligence		103
Figure C.1	Distribution of Total Oncology Indications in various Development (4264 Active Cancer Drug Indications for 2231 Cancer Drugs under development) A. Relative Number of Cancer Drug Indications for Small Molecules vs Biologics vs Others. B. Comparative Clinical, Preclinical & Discovery Indications under development.	104
Figure C.2	Distribution of 4264 cancer drug development indications among USA, Europe, Asia and RoW.	104
Figure C.3	Cancer Clinical Indications Development Strategies:- A. Total indications in clinical trials – Top 10 companies vs remaining 513 companies. B. Top 10 companies clinical pipeline indications – Small Molecules vs Biologics. C. Remaining 513 companies clinical pipeline indications - Small Molecules vs Biologics vs NBCM.	104
Figure C.4	Global incidence of Lung Cancer .	106
Figure C.5	A. Lung Cancer treatment molecules vs. total number of molecules in various development stages for cancer treatment. B. Companies with active drug development pipeline for Lung Cancer treatment vs. total number of companies worldwide, with cancer drug pipeline.	109
Figure C.6	Exploring Lung Cancer Development Strategies:- A. Comparison between Top 10 Companies, Lung cancer clinical pipeline vs. remaining other clinical companies pipeline molecules. B. Percentage of molecules in development for Lung Cancer, between U.S.A vs. Europe vs. RoW.	109
Figure C.7	A. Phase-wise division of total Lung Cancer molecules in various developmental stages. B. Subtype division of Lung Cancer's <i>Phase II</i> clinical molecules- <i>Small, Biologics & NBCM</i> . C. Subtype division of Lung Cancer's <i>Phase I</i> clinical molecules- <i>Small, Biologics & NBCM</i> .	109
Figure C.8	A. Distribution of Lung Cancer Pipeline in <i>Small, Biologics & NBCM</i> . B. Distribution of <i>Vaccines, Monoclonal Antibodies & other Biologics among PhI, II, III & Preclinical/ Discovery</i> development phases.	110
Figure C.9	Global incidence of Breast Cancer .	115
Figure C.10	A. Breast Cancer treatment molecules vs. total number of molecules in various development stages for cancer treatment. B. Companies with active drug development pipeline for Breast Cancer treatment vs. total number of companies worldwide, with cancer drug pipeline.	118
Figure C.11	Exploring Breast Cancer Development Strategies:- A. Comparison between Top 10 Companies, Breast cancer clinical pipeline vs. remaining other clinical companies pipeline molecules. B. Percentage of molecules in development for Breast Cancer, between USA vs. Europe vs. RoW.	118
Figure C.12	A. Phase-wise division of total Breast Cancer molecules in various developmental stages. B. Subtype division of Breast Cancer's <i>Phase II</i> clinical molecules- <i>Small, Biologics & NBCM</i> . C. Subtype division of Breast Cancer's <i>Phase I</i> clinical molecules- <i>Small, Biologics & NBCM</i> .	118
Figure C.13	A. Distribution of Breast Cancer Pipeline in <i>Small, Biologics & NBCM</i> . B. Distribution of <i>Vaccines, Monoclonal Antibodies & other Biologics among PhI, II, III & Preclinical/ Discovery</i> development phases.	119
Figure C.14	Global incidence of Colorectal Cancer .	123
Figure C.15	A. Colorectal Cancer treatment molecules vs. total number of molecules in various development stages for cancer treatment. B. Companies with active drug development pipeline for Colorectal Cancer treatment vs. total number of companies worldwide, with cancer drug pipeline.	125

Figure C.16	Exploring Colorectal Cancer Development Strategies:-	125
	A. Comparison between Top 10 Companies, Colorectal cancer clinical pipeline vs. remaining other clinical companies pipeline molecules.	
	B. Percentage of molecules in development for Colorectal Cancer among USA vs. Europe vs. RoW.	
Figure C.17	A. Phase-wise division of total Colorectal Cancer molecules in various developmental stages.	125
	B. Subtype division of Colorectal Cancer's <i>Phase II</i> clinical molecules- <i>Small, Biologics & NBCM</i> .	
	C. Subtype division of Colorectal Cancer's <i>Phase I</i> clinical molecules- <i>Small, Biologics & NBCM</i> .	
Figure C.18	A. Distribution of Colorectal Cancer Pipeline in <i>Small, Biologics & NBCM</i> .	126
	B. Distribution of <i>Vaccines, Monoclonal Antibodies & other Biologics</i> among <i>PhI, II, III & Pre clinical/ Discovery</i> development phases.	
Figure C.19	Global incidence of Melanoma Cancer.	129
Figure C.20	A. Melanoma Cancer treatment molecules vs. total number of molecules in various development stages for cancer treatment.	131
	B. Companies with active drug development pipeline for Melanoma Cancer treatment vs. total number of companies worldwide, with cancer drug pipeline.	
Figure C.21	Exploring Melanoma Cancer Development Strategies:-	131
	A. Comparison between Top 10 Companies, Melanoma cancer clinical pipeline vs. remaining other clinical companies pipeline molecules.	
	B. Percentage of molecules in development for Lung Cancer, between USA vs. Europe vs. RoW.	
Figure C.22	A. Phase-wise division of total Melanoma Cancer molecules in various developmental stages.	131
	B. Subtype division of Melanoma Cancer's <i>Phase II</i> clinical molecules- <i>Small, Biologics & NBCM</i> .	
	C. Subtype division of Melanoma Cancer's <i>Phase I</i> clinical molecules- <i>Small, Biologics & NBCM</i> .	
Figure C.23	A. Distribution of Melanoma Cancer Pipeline in <i>Small, Biologics & NBCM</i> .	132
	B. Distribution of <i>Vaccines, Monoclonal Antibodies & other Biologics</i> among <i>PhI, II, III & Preclinical/ Discovery</i> development phases.	
Figure C.24	Global incidence of Prostate Cancer.	136
Figure C.25	A. Prostate Cancer treatment molecules vs. total number of molecules in various development stages for cancer treatment.	138
	B. Companies with active drug development pipeline for Prostate Cancer treatment vs. total number of companies worldwide, with cancer drug pipeline.	
Figure C.26	Exploring Prostate Cancer Development Strategies:-	138
	A. Comparison between Top 10 Companies, Prostate cancer clinical pipeline vs. remaining other clinical companies pipeline molecules.	
	B. Percentage of molecules in development for Prostate Cancer, between USA vs. Europe vs. RoW.	
Figure C.27	A. Phase-wise division of total Prostate Cancer molecules in various developmental stages.	138
	B. Subtype division of Prostate Cancer's <i>Phase II</i> clinical molecules- <i>Small, Biologics & Others</i> .	
	C. Subtype division of Prostate Cancer's <i>Phase I</i> clinical molecules- <i>Small, Biologics & Others</i> .	
Figure C.28	A. Distribution of Prostate Cancer Pipeline in <i>Small, Biologics & NBCM</i> .	139
	B. Distribution of <i>Vaccines, Monoclonal Antibodies & other Biologics</i> among <i>PhI, II, III & Preclinical/ Discovery</i> development phases.	
Figure C.29	Global incidence of Ovarian Cancer.	143
Figure C.30	A. Ovarian Cancer treatment molecules vs. total number of molecules in various developmental stages for cancer treatment.	145
	B. Companies with active drug development pipeline for Ovarian Cancer treatment vs. total number of companies worldwide, with cancer drug pipeline.	

Figure C.31	Exploring Ovarian Cancer Development Strategies:-	145
	A. Comparison between Top 10 Companies, Ovarian cancer clinical pipeline vs. remaining other clinical companies pipeline molecules.	
	B. Percentage of molecules in development for Ovarian Cancer, between USA vs. Europe vs. RoW.	
Figure C.32	A. Phase-wise division of total Ovarian Cancer molecules in various developmental stages.	145
	B. Subtype division of Ovarian Cancer's <i>Phase II</i> clinical molecules- <i>Small, Biologics & NBCM</i> .	
	C. Subtype division of Ovarian Cancer's <i>Phase I</i> clinical molecules- <i>Small, Biologics & NBCM</i> .	
Figure C.33	A. Distribution of Ovarian Cancer Pipeline in <i>Small, Biologics & NBCM</i> .	146
	B. Distribution of <i>Vaccines, Monoclonal Antibodies & other Biologics</i> among PhI, II, III & Preclinical/ Discovery development phases.	
Figure C.34	Global incidence of Pancreatic Cancer.	151
Figure C.35	A. Pancreatic Cancer treatment molecules vs. total number of molecules in various developmental stages for cancer treatment.	153
	B. Companies with active drug development pipeline for Pancreatic Cancer treatment vs. total number of companies worldwide, with cancer drug pipeline.	
Figure C.36	Exploring Pancreatic Cancer Development Strategies:-	153
	A. Comparison between Top 10 Companies, Pancreatic cancer clinical pipeline vs. remaining other clinical companies pipeline molecules.	
	B. Percentage of molecules in development for Pancreatic Cancer, between USA vs. Europe vs. RoW.	
Figure C.37	A. Phase-wise division of total Pancreatic Cancer molecules in various development stages.	153
	B. Subtype division of Pancreatic Cancer's <i>Phase II</i> clinical molecules- <i>Small, Biologics & NBCM</i> .	
	C. Subtype division of Pancreatic Cancer's <i>Phase I</i> clinical molecules- <i>Small, Biologics & NBCM</i> .	
Figure C.38	A. Distribution of Pancreatic Cancer Pipeline in <i>Small, Biologics & NBCM</i> .	154
	B. Distribution of <i>Vaccines, Monoclonal Antibodies & other Biologics</i> among PhI, II, III & Preclinical/ Discovery development phases.	
Figure C.39	Global incidence of Hepatocellular Carcinoma.	158
Figure C.40	Global incidence of Gastric Cancer.	161
Figure C.41	Global incidence of Multiple Myeloma.	163
Figure C.42	Global incidence of Leukemia.	165
Figure C.43	Global incidence of Non-Hodgkin Lymphoma.	171
Figure C.44	Global incidence of Hodgkin Lymphoma.	175
Figure C.45	Global incidence of Brain Cancer including Glioblastoma.	176
Figure C.46	Global incidence of Head & Neck Cancer.	179
Figure C.47	Global incidence of Renal Cell Carcinoma.	182
Figure C.48	Global incidence of Bladder Cancer.	185
Figure C.49	Global incidence of Thyroid Cancer.	187

List of Tables:

Section A : Oncology Companies with Active Drug Development Pipeline- *Infographics* 31

Table A.1	Top 10 Cancer drug development companies (in terms of employee number).	38
------------------	---	-----------

Section B : Active Oncology Drugs & Targets in Development - *Intelligence* 39

Table B.1	Top 20 companies with highest number of cancer clinical molecules in development.	42
Table B.2	Monoclonal Antibodies in Clinical Trials (174 Molecules- their developer, partner, target, isotypes & indications).	43
Table B.3	Monoclonal Antibodies in Preclinical & Discovery stage (193 Molecules- their developer, target & indications).	49
Table B.4	Cancer Vaccines in Clinical development (134 Vaccines-their developer, partner, target, indications & comments).	52
Table B.5	Cancer Vaccines in Preclinical & Discovery development stage (50 Vaccines-their developer, target & indications).	58
Table B.6	Antibody Drug Conjugates in Clinical development (42 Molecules, developer, partner, target, indications & comments).	59
Table B.7	Radio-Immuno Conjugates in Clinical Development (10 Molecules, developer, partner, target, indications, comments).	61
Table B.8	Recombinant/Fusion Proteins based therapies in Clinical Development (49 Molecules, developer, partner, target, indications, comments).	62
Table B.9	Synthetic Peptides based therapies in Clinical Trials (19 Molecules, developer, partner, target, indications, comments).	64
Table B.10	Gene Therapies & Oncolytic based therapies in Clinical Development (33 Molecules, developer, partner, target, indications, comments).	65
Table B.11	T cell based therapies in Clinical Trials (8 Molecules, developer, partner, target, indications, comments).	67
Table B.12	Stem cell based therapies in Clinical Trials (6 Molecules, developer, partner, target, indications, comments).	67
Table B.13	Other cell based therapies in Clinical Trials (5 Molecules, developer, partner, target, indications, comments).	67
Table B.14	Miscellaneous other Biologics in Clinical Trials (19 Molecules, developer, partner, target, indications, comments).	68
Table B.15	Approved Kinase Inhibitors for Cancer Cure (Developer, type, target, approved since, 2013 sales, indications).	70
Table B.16	Expected New Kinases Launches in 2014-15 (Drug, developer, type, target, expected launch & indication).	71
Table B.17	Cancer Drug Targets - Protein Kinases (Individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target's description).	72
Table B.18	Cancer Drug Targets - Tumor Necrosis Factor Family (Individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target's Description).	80
Table B.19	Cancer Drug Targets - G-coupled Protein Receptors (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target's Description).	82
Table B.20	Cancer Drug Targets - Tumor Antigens (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target's Description).	83
Table B.21	Cancer Drug Targets - Transcription Factors (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target's Description).	85
Table B.22	Cancer Drug Targets - Metabolic Enzymes (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, Target's Description).	87
Table B.23	Cancer Drug Targets - Growth Factors (individual target name, Gene, protein family, cellular function/location, Drugs in development for the target, target Description).	89
Table B.24	Cancer Drug Targets - Miscellaneous other Targets (individual target name, Gene, protein family, Drugs in development for the target, target Description).	90

Section C: Oncology Indications in various Development Stages - *Intelligence* 103

Table C.1	Molecule Development Strategies - Top 10 companies Vs. Remaining 921 companies (Comparison between total molecules, clinical phases, types, top 7 targets, top 9 indications and market capitalization).	105
Table C.2	Top selling chemotherapies for Lung Cancer .	107
Table C.3	Top selling targeted therapies for Lung Cancer.	107
Table C.4	Molecules in Ph III clinical trials for NSCLC (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	108

Table C.5	Monoclonal Antibodies in various drug development stages for the treatment of Lung Cancer.	110
Table C.6	Vaccines in various drug development stages for the treatment of Lung Cancer.	110
Table C.7	Miscellaneous other Biologics in various drug development stages for the treatment of Lung Cancer.	111
Table C.8	Non Small Lung Cancer (NSCLC) Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	111
Table C.9	Molecules in Ph III clinical trials for Lung Cancer (SCLC) (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).	114
Table C.10	Small Cell Lung Cancer (SCLC) Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	114
Table C.11	Top selling Chemotherapies/Hormonal Therapies for Breast Cancer .	116
Table C.12	Top selling Targeted Therapies for Breast Cancer.	116
Table C.13	Molecules in Ph III clinical trials for Breast Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).	117
Table C.14	Monoclonal Antibodies in various drug development stages for the treatment of Breast Cancer.	119
Table C.15	Vaccines in various drug development stages for the treatment of Breast Cancer.	119
Table C.16	Miscellaneous other Biologics in various drug development stages for the treatment of Breast Cancer.	120
Table C.17	Breast Cancer Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	120
Table C.18	Top selling chemotherapies for Colorectal Cancer .	124
Table C.19	Top selling targeted therapies for Colorectal Cancer.	124
Table C.20	Molecules in Ph III clinical trials for Colorectal Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).	124
Table C.21	Monoclonal Antibodies in various drug development stages for the treatment of Colorectal Cancer.	126
Table C.22	Vaccines in various drug development stages for the treatment of Colorectal Cancer.	126
Table C.23	Miscellaneous other Biologics in drug development stages for the treatment of Colorectal Cancer.	127
Table C.24	Colorectal Cancer Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	127
Table C.25	Top selling chemotherapies for Melanoma Cancer .	130
Table C.26	Top selling targeted therapies for Melanoma Cancer.	130
Table C.27	Molecules in Ph III clinical trials for Melanoma Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).	130
Table C.28	Monoclonal Antibodies in various drug development stages for the treatment of Melanoma Cancer.	132
Table C.29	Vaccines in various drug development stages for the treatment of Melanoma Cancer.	132
Table C.30	Miscellaneous other Biologics in drug development stages for the treatment of Melanoma Cancer.	133
Table C.31	Melanoma Cancer Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	134
Table C.32	Other Skin Cancers Including Non-Melanoma Cancer Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	135
Table C.33	Top selling Chemotherapies for Prostate Cancer .	137
Table C.34	Top selling Targeted therapies for Prostate Cancer.	137
Table C.35	Molecules in Ph III clinical trials for Prostate Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).	137
Table C.36	Monoclonal Antibodies in various drug development stages for the treatment of Prostate Cancer.	139
Table C.37	Vaccines in various drug development stages for the treatment of Prostate Cancer.	139
Table C.38	Miscellaneous other Biologics in drug development stages for the treatment of Prostate Cancer.	140
Table C.39	Prostate Cancer Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	140
Table C.40	Top selling chemotherapies for Ovarian Cancer .	144
Table C.41	Molecules in Ph III clinical trials for Ovarian Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).	144
Table C.42	Monoclonal Antibodies in various drug development stages for the treatment of Ovarian Cancer.	146
Table C.43	Vaccines in various drug development stages for the treatment of Ovarian Cancer.	146
Table C.44	Miscellaneous other Biologics in drug development stages for the treatment of Ovarian Cancer.	147
Table C.45	Ovarian Cancer Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	147

Table C.46	<i>Cervical Cancer Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	149
Table C.47	<i>Fallopian Tube Cancer Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	149
Table C.48	<i>Peritoneal Cancer Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	149
Table C.49	<i>Endometrial Cancer Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	149
Table C.50	Top selling chemotherapies for Pancreatic Cancer .	152
Table C.51	Top selling targeted therapies for Pancreatic Cancer.	152
Table C.52	Molecules in Ph III clinical trials for Pancreatic Cancer (Drug, developer, partner, indications, combination drug in trial, line of therapy, target, expected launch).	152
Table C.53	Monoclonal Antibodies in various drug development stages for the treatment of Pancreatic Cancer.	154
Table C.54	Vaccines in various drug development stages for the treatment of Pancreatic Cancer.	154
Table C.55	Miscellaneous other Biologics in drug development stages for the treatment of Pancreatic Cancer.	155
Table C.56	<i>Pancreatic Cancer Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	155
Table C.57	<i>Neuroendocrine Cancer Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	156
Table C.58	<i>Esophageal Cancer Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	157
Table C.59	<i>GastroIntestinal Stromal Tumor Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	157
Table C.60	<i>Biliary Tract Cancer Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	157
Table C.61	<i>GallBladder Cancer Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	157
Table C.62	<i>Midgut Carcinoid Cancer Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	157
Table C.63	<i>Cholangiocarcinoma Cancer Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	157
Table C.64	<i>Anal Cancer Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	157
Table C.65	Top selling targeted therapies for Hepatocellular Carcinoma .	159
Table C.66	Molecules in Ph III clinical trials for Hepatocellular Carcinoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	159
Table C.67	<i>Hepatocellular Carcinoma Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	159
Table C.68	Top selling targeted therapies for Gastric Cancer .	161
Table C.69	Molecules in Ph III clinical trials for Gastric Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	162
Table C.70	<i>Gastric Cancer Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	162
Table C.71	Molecules in Ph III clinical trials for Multiple Myeloma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	163
Table C.72	<i>Multiple Myeloma Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	164
Table C.73	Top selling targeted therapies for Leukemia .	166
Table C.74	Molecules in Ph III clinical trials for Leukemia (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	166
Table C.75	<i>Acute Myeloid Leukemia Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	167
Table C.76	<i>Acute Myelogenous Leukemia Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	168
Table C.77	<i>Acute Lymphoid Leukemia Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	169
Table C.78	<i>Acute Lymphocytic Leukemia Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	169
Table C.79	<i>Chronic Myeloid Leukemia Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	169
Table C.80	<i>Chronic Myelogenous Leukemia Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	169
Table C.81	<i>Chronic Myelomonocytic Leukemia Pipeline</i> - Clinical stage drugs, developers, partners & targets.	169
Table C.82	<i>Chronic Lymphoid Leukemia Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	170
Table C.83	Top selling targeted therapies for Non Hodgkin Lymphoma .	172
Table C.84	Molecules in Ph III clinical trials for Non Hodgkin Lymphoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	172
Table C.85	<i>Non Hodgkin Lymphoma Pipeline</i> - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	173
Table C.86	Waldenstrom's Macroglobulinemia- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	174

Table C.87	Molecules in Ph III clinical trials for Hodgkin Lymphoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	175
Table C.88	Hodgkin Lymphoma Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	175
Table C.89	Molecules in Ph III clinical trials for Brain Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	177
Table C.90	Glioblastoma Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	177
Table C.91	Neuroblastoma Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	178
Table C.92	Medullolastoma Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	178
Table C.93	Anaplastic Astrocytoma Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	178
Table C.94	Top selling targeted therapies for Head & Neck Cancer .	180
Table C.95	Molecules in Ph III clinical trials for Head & Neck Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	180
Table C.96	Head & Neck Cancer Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	180
Table C.97	Nasopharynx Cancer Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	181
Table C.98	Oral Cancer Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	181
Table C.99	Top selling targeted therapies for Renal Cell Carcinoma .	183
Table C.100	Molecules in Ph III clinical trials for Renal Cell Carcinoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	183
Table C.101	Renal Cell Carcinoma Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	183
Table C.102	Wilm's Tumor Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	184
Table C.103	Top selling targeted therapies for Bladder Cancer .	186
Table C.104	Molecules in Ph III clinical trials for Bladder Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	186
Table C.105	Bladder Cancer Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	186
Table C.106	Top selling targeted therapies for Thyroid Cancer .	188
Table C.107	Molecules in Ph III clinical trials for Thyroid Cancer (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	188
Table C.108	Thyroid Cancer Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	188
Table C.109	Molecules in Ph III clinical trials for Sarcoma (Drug, developer, partner, indications, combination drugs in trial, line of therapy, target, expected launch).	189
Table C.110	Sarcoma Pipeline - Clinical, Preclinical & Discovery stage drugs, developers, partners & targets).	189
Table C.111	Other Rare Cancer Indications Pipeline- Clinical, Preclinical & Discovery stage drugs, developers, partners & targets.	191
Table C.112	Orphan Drug Status cancer molecules in clinical development (145 Molecules with 174 orphan indications) (Drug Name, Phase, Orphan indication, developer, USFDA/EMA approvals).	192
Table C.113	US FDA New Oncology Drug Approvals -2013 (Developer, month of approval, partner, drug proprietary name, established name, approved indications with disease state)	195
Table C.114	Oncology Clinical Pipeline- Major Drug Failures 2013 (Drug, Developer, month, phase, indications, comments).	196

List of Boxes:

Section C: Oncology Indications in various Development Stages - Intelligence		103
Box C.1	Lung Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	106
Box C.2	Strong Clinical Pipeline Companies - Lung Cancer.	109
Box C.3	Breast Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	115
Box C.4	Strong Clinical Pipeline Companies - Breast Cancer.	118
Box C.5	Colorectal Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	123
Box C.6	Strong Clinical Pipeline Companies - Colorectal Cancer.	125
Box C.7	Melanoma Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	129
Box C.8	Strong Clinical Pipeline Companies - Melanoma Cancer.	131
Box C.9	Prostate Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	136
Box C.10	Strong Clinical Pipeline Companies - Prostate Cancer.	138
Box C.11	Ovarian Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	143
Box C.12	Strong Clinical Pipeline Companies - Ovarian Cancer.	145
Box C.13	Other Gynaecologic Malignancies Indications.	149
Box C.14	Pancreatic Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	151
Box C.15	Strong Clinical Pipeline Companies - Pancreatic Cancer.	153
Box C.16	Other Gastrointestinal Indications.	157
Box C.17	Hepatocellular Carcinoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	158
Box C.18	Gastric Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	161
Box C.19	Multiple Myeloma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	163
Box C.20	Leukemia- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	165
Box C.21	NonHodgkin Lymphoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	171
Box C.22	Hodgkin Lymphoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	175
Box C.23	Brain Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	176
Box C.24	Head & Neck Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	179
Box C.25	Renal Cell Carcinoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	182
Box C.26	Bladder Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	185
Box C.27	Thyroid Cancer- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	187
Box C.28	Sarcoma- An Overview, Current & Forecast Epidemiology (U.S.A & Worldwide), Current Drug Market Size & Sales Forecast.	189